Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46

Alterations in ATC/DDD

Overview of ATC/DDD alterations decided at the two previous meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC/DDD alterations from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the alterations will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list. 

Please note that all ATC and DDD alterations are valid and implemented annually.


Change in ATC codes

INN/generic namePrevious ATC codeNew ATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
methotrexate 2)L01BA01L04AX03Final2017
nonacog alfaB02BD09B02BD04 3)Final2017
trenonacog alfaB02BD12B02BD04 3)Final2017
1) Final: indicates that the date for objection has expired
2) Splitting of ATC code. Only the classification of pre-filled syringes of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATC code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in L01BA01.
3) Existing ATC code B02BD04 coagulation factor IX

Change of ATC level name

Previous nameNew ATC level nameATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
atenolol and other antihypertensivesatenolol and nifedipineC07FB03Final2017
Beta blocking agents and other antihypertensivesBeta blocking agents, other combinationsC07FFinal2017
Beta blocking agents, selective, and other antihypertensivesBeta blocking agents and calcium channel blockersC07FBFinal2017
bisoprolol and other antihypertensivesbisoprolol and amlodipineC07FB07Final2017
nebivolol and other antihypertensivesnevibolol and amlodipineC07FB12Final2017
oxycodone, combinationoxycodone and naloxoneN02AA55Final2017
1) Final: indicates that the date for objection has expired

Change of ATC code and/or ATC level name based on new ATC 4th levels established

Final, will be included in the ATC/DDD Index valid from 2017.

Previous ATC code and level nameNew ATC code and/or level name
C07FXBeta blocking agents, other combinations
N02AJOpioids in combination with non-opioid analgesics
C07AA57sotalol, combinationsC07FX02sotalol and acetylsalicylic acid
C07AB52metoprolol, combinationsC07FX03metoprolol and acetylsalicylic acid
C07AB57bisoprolol, combinationsC07FX04bisoprolol and acetylsalicylic acid
C07FABeta blocking agents, non-selective, and other antihypertensivesDeleted
C07FA05propranolol and other antihypertensivesC07FX01propranolol and other combinations
C07FB02 1)metoprolol and other antihypertensivesC07FB02
metoprolol and felodipine 2)
metoprolol and amlodipine
N02AA55 3)oxycodone, combinations 5)N02AJ19 4)oxycodone and ibuprofen
N02AA55 3)
N02BA51 3)
oxycodone, combinations 5)
acetylsalicylic acid, combinations excl. psycholeptics
N02AJ18 4)oxycodone and acetylsalicylic acid
N02AA55 3)
N02BE51 3)
oxycodone, combinations 5)
paracetamol, combinations excl. psycholeptics
N02AJ17 4)oxycodone and paracetamol
N02AA58 3)dihydrocodeine, combinationsN02AJ01 4)dihydrocodeine and paracetamol
N02AA58 3)dihydrocodeine, combinationsN02AJ02 4)dihydrocodeine and acetylsalicylic acid
N02AA58 3)dihydrocodeine, combinationsN02AJ03 4)dihydrocodeine and other non-opioid analgesics
N02AA59 3)codeine, combinations excl. psycholepticsN02AJ09 4)codeine and other non-opioid analgesics
N02AA59 3)
M01AE51 3)
codeine, combinations excl. psycholeptics
ibuprofen, combinations
N02AJ08 4)codeine and ibuprofen
N02AA59 3)
N02BA51 3)
codeine, combinations excl. psycholeptics
acetylsalicylic acid, combinations excl. psycholeptics
N02AJ07 4)codeine and acetylsalicylic acid
N02AA59 3)
N02BE51 3)
codeine, combinations excl. psycholepticsN02AJ06 4)codeine and paracetamol
N02AX52tramadol, combinationsN02AJ13tramadol and paracetamol
N02BA51 3)acetylsalicylic acid, combinations excl. psycholeptics
N02BE51 3)paracetamol, combinations excl. psycholeptics
1) Splitting of ATC code in connection with alterations in C07FX
2) Existing ATC code
3) Splitting of ATC codes according to contents of the different fixed combinations of opioids and other analgesics. The ATC codes in N02AA, N02BA51, N02BE51 and M01AE51 will be maintained for other combinations.
4) Combinations with opioids and other analgesics currently classified in the following ATC codes N02AA55, N02AA58, N02AA59 will be moved to the new ATC 4th level N02AJ. All the existing combination codes will be kept in N02AA since there may be other combinations without analgesics available (e.g. oxycodone and naloxone will remain in N02AA55). The ATC classification of all low dose combinations products of codeine or dihydrocodeine (<20 mg dose) currently classified in N02B or M01A will be altered to the new ATC codes in N02AJ
5) Combinations of oxycodone and naloxone will be maintained in N02AA55

Change of DDDs

ATC codeLevel namePrevious DDDNew DDDDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
A16AX01thioctic acid0.2 g O,P0.6 g O,P01.09.20162017
B02BDBlood coagulation factors 2)deleted 2)Final2017
G03XB01mifepristone0.6 g O0.2 g OFinal2017
J01CR01ampicillin and enzyme inhibitor 2 g 3) P6 g O01.02.20162017
J02AC04posaconazole0.8 g O0.3 g O01.09.20162017
1) Final: indicates that the date for objection has expired
2) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
3) Refers to ampicillin

Last updated: 2016-11-01